Back to News
Market Impact: 0.3
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
Source: zacks.com
Healthcare & BiotechTechnology & InnovationRegulation & Legislation
Editas Medicine received approval to launch a first-in-human Phase I/II study of EDIT-401 in Australia. The gene-editing candidate targets LDL cholesterol; the approval enables clinical testing but does not establish safety or efficacy.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
EDIT0.75
More News
- Verizon stock heads for worst day since 2002 as SpaceX U.S. network plans whack telcos
- Elon Musk intensifies attack on Ambani over Starlink India launch delay
- What's behind the recovery rally in tech stocks — plus, Elon Musk's very good week
- SpaceX’s Wireless Threat Rises With Spectrum Deal
- ‘Piece by piece’: Trump administration vows to dismantle the International Criminal Court with sweeping new sanctions
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Advanced Search Filters, Redesigned Ticker Dashboard, and Improved Search Experience
- How to Build an Automated Research Process for a Fund